Vimarsana
Biggest News Aggregation in the World

Page 21 - Nuclear Export News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Nuclear Export. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Nuclear Export Today - Breaking & Trending Today

Karyopharm Announces Presentation of Updated Phase 1 Selinexor Data in Patients with Treatment-Naïve Myelofibrosis at ASH 2022 - Vimarsana News

Karyopharm Announces Presentation of Updated Phase 1 Selinexor Data in Patients with Treatment-Naïve Myelofibrosis at ASH 2022

Published: December 12, 2022

/PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced...

Source: prnewswire.com
Related Topics:
United StatesHong KongUnited KingdomKyongsang BuktoSouth KoreaHaris AliSrdan VerstovsekReshma RangwalaSelective Inhibitor Of Nuclear ExportKaryopharm Therapeutics IncDrug AdministrationMd Anderson Cancer CenterPrnewswire Karyopharm Therapeutics IncAmerican Society Of HematologyExchange CommissionEuropean UnionKaryopharm Selective Inhibitor Of Nuclear ExportCompany To Host InvestorCity Of Hope Comprehensive Cancer CenterInformation DepartmentEfficacy Evaluable PatientsHost InvestorAnalyst Webcast Featuring Key OpinionAmerican SocietyChief Medical Officer
Karyopharm Announces $165 Million Private Placement - Vimarsana News

Karyopharm Announces $165 Million Private Placement

Published: December 5, 2022

/PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that...

Source: prnewswire.com
Related Topics:
United StatesUnited KingdomMarshall WacePiper SandlerSelective Inhibitor Of Nuclear ExportKaryopharm Therapeutics IncDrug AdministrationPrnewswire Karyopharm Therapeutics IncExchange CommissionSecurities ExchangeHc Wainwright CoAvidity PartnersAdage Capital PartnersArmistice CapitalHealthcor ManagementHeights Capital ManagementRubric Capital ManagementSilverarc CapitalSurveyor CapitalSecurities ActSelective InhibitorNuclear ExportSecurities Exchange ActQuarterly ReportKaryopharm Therapeutics
Karyopharm Announces Investor and Analyst Event at ASH 2022 on Selinexor Data in Patients with Treatment-Naïve Myelofibrosis - Vimarsana News

Karyopharm Announces Investor and Analyst Event at ASH 2022 on Selinexor Data in Patients with Treatment-Naïve Myelofibrosis

Published: December 5, 2022

/PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced it...

Source: prnewswire.com
Related Topics:
United StatesHong KongUnited KingdomKyongsang BuktoSouth KoreaHaris AliSrdan VerstovsekSelective Inhibitor Of Nuclear ExportSection Leader For Leukemia DivisionMd Anderson Cancer CenterCompany Sponsored Event OnClinical Research For Myeloproliferative NeoplasmsAmerican Society Of HematologyEuropean UnionKaryopharm Selective Inhibitor Of Nuclear ExportNuclear Transport Inhibition In MyelofibrosisInformation DepartmentKaryopharm Therapeutics IncDavid Geffen School Of MedicineDrug AdministrationPrnewswire Karyopharm Therapeutics IncExchange CommissionCity Of Hope Comprehensive Cancer CenterKey Opinion LeadersPreview Highlights
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Vimarsana News

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Published: December 1, 2022

/PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that...

Source: prnewswire.com
Related Topics:
United KingdomSouth KoreaSelective Inhibitor Of Nuclear ExportPrnewswire Karyopharm Therapeutics IncKaryopharm Therapeutics IncStock Incentive PlanNasdaq Listing RuleSelective InhibitorNuclear ExportKaryopharm TherapeuticsKaryopharm Therapeutics Inc
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Vimarsana News

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Published: December 1, 2022

/PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that...

Source: prnewswire.com
Related Topics:
United KingdomSouth KoreaSelective Inhibitor Of Nuclear ExportPrnewswire Karyopharm Therapeutics IncKaryopharm Therapeutics IncStock Incentive PlanNasdaq Listing RuleSelective InhibitorNuclear ExportKaryopharm Therapeutics